Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul;203(5):2043-2057.
doi: 10.1007/s00203-021-02183-z. Epub 2021 Feb 8.

COVID-19: molecular pathophysiology, genetic evolution and prospective therapeutics-a review

Affiliations
Review

COVID-19: molecular pathophysiology, genetic evolution and prospective therapeutics-a review

C T Dhanya Raj et al. Arch Microbiol. 2021 Jul.

Abstract

The Covid-19 pandemic is highly contagious and has spread rapidly across the globe. To date there have been no specific treatment options available for this life-threatening disease. During this medical emergency, target-based drug repositioning/repurposing with a continuous monitoring and recording of results is an effective method for the treatment and drug discovery. This review summarizes the recent findings on COVID-19, its genomic organization, molecular evolution through phylogenetic analysis and has recapitulated the drug targets by analyzing the viral molecular machinery as drug targets and repurposing of most frequently used drugs worldwide and their therapeutic applications in COVID-19. Data from solidarity trials have shown that the treatment with Chloroquine, hydroxychloroquine and lopinavir-ritonavir had no effect in reducing the mortality rate and also had adverse side effects. Remdesivir, Favipiravir and Ribavirin might be a safer therapeutic option for COVID-19. Recent clinical trial has revealed that dexamethasone and convalescent plasma treatment can reduce mortality in patients with severe forms of COVID-19.

Keywords: COVID-19; Dexamethasone; Drug repositioning/repurposing; Favipiravir; Molecular targets; Remdesivir; Ribavarin.

PubMed Disclaimer

Conflict of interest statement

None of the authors have any conflict of interest to declare.

Figures

Fig. 1
Fig. 1
Structure of corona virus, reproduced from Li
Fig. 2
Fig. 2
Genome organization of SARS-CoV-2, SARS-CoV, and MERS. Reproduced from Mousavizadeh and Ghasemi
Fig. 3
Fig. 3
Phylogenomic tree inferred using the formula D6 (GBDP_Trimming_D6_FASTME). The numbers above branches are bootstrap support values from 100 replications

Similar articles

Cited by

References

    1. Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, Smith EC, Case JB, Feng JY, Jordan R, Ray AS, Cihlar T, Siegel D, Mackman RL, Clarke MO, Baric RS, Denison MR. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio. 2018;9:2. doi: 10.1128/mBio.00221-18. - DOI - PMC - PubMed
    1. Agrawal U, Raju R, Udwadia ZF. Favipiravir: a new and emerging antiviral option in COVID-19. Med J Arm Forc India. 2020;76(4):370–376. doi: 10.1016/j.mjafi.2020.08.004. - DOI - PMC - PubMed
    1. Angeletti S, Benvenuto D, Bianchi M, Giovanetti M, Pascarella S, Ciccozzi M. COVID-2019: the role of the nsp2 and nsp3 in its pathogenesis. J Med Virol. 2020;92(6):584–588. doi: 10.1002/jmv.25719. - DOI - PMC - PubMed
    1. Báez-Santos YM, St John SE, Mesecar AD. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds. Antiviral Res. 2015;115:21–38. doi: 10.1016/j.antiviral.2014.12.015. - DOI - PMC - PubMed
    1. Ballout RA, Sviridov D, Bukrinsky MI, Remaley AT. The lysosome: A potential juncture between SARS-CoV-2 infectivity and Niemann-Pick disease type C, with therapeutic implications. FASEB J Off Publ Feder Am Soc Exp Biol. 2020;34(6):7253–7264. doi: 10.1096/fj.202000654R. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources